Business
Telo Genomics Presents Superior Results of Its Smoldering Multiple Myeloma Studies at ASCO 2023
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDS...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Presents Superior Results of Its Smoldering Multiple Myeloma Studies at ASCO 2023Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented earlier today at the American Society of Clinical Oncology (ASCO) 2023 annual meeting. A total of 178 SMM patients were included in the study. The study results revealed a superior accuracy of 80% to stratify the SMM patients to their respective risk groups. The superior test accuracy was accompanied by over 80% precision in identifying high-risk SMM patients, and over 75% precision in identifying low-risk SMM patients. Currently there is no prognostic test in the clinic able to stratify accurately SMM patients to their respective risk groups, potentially presenting low to no competition to the TeloView test. Yet the achieved characteristics of the TeloView test for SMM patients are considered superior to the characteristics of similar prognostic tests for other cancer indications that are currently used in the clinic. Telo has conducted clinical studies in collaboration with the Mayo Clinic to validate the utility of its lead product for SMM patients. The test is designed to identify high-risk SMM patients who will benefit from immediate treatment intervention and confirm the disease stability in low-risk SMM patients that can be safely monitored over time using the TeloView test without treatment intervention. There are over 200,000 SMM patients in the US that may benefit from TeloView SMM test, with a potential total addressable market of over 500,000 tests per year.\"SMM patients in my practice present a unique challenge in terms of both monitoring strategy and treatment options,\" said Dr. Richard Bender, M.D., FACP, Telo's Chair of MM Advisory Board, Senior member of The Oncology Institute of Hope and Innovation and former Medical Director at Quest Diagnostics. \"These new data from Telo Genomics and the Mayo Clinic represent an important new tool that may help to optimize surveillance and therapy decisions for this growing group of patients. I look forward to the availability of TeloView SMM in clinical practice.\"\"We are thrilled to present...